Your AI-Trained Oncology Knowledge Connection!

Advancements in Treatment Management Strategies for EGFR-Mutated NSCLC: Insights from Experts at The University of California Irvine : Episode 6

Educating Patients and Clinical Staff on Infusion-Related Adverse Reactions Seen With Amivantamab in NSCLC With EGFR Exon 20 Mutations

October 23, 2023

By Misako Nagasaka, MD, PhD
Kristen Neumann, DNP, FNP-C

Opinion

Video

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, discuss the importance of early dermatological consultations and multidisciplinary education for managing infusion-related adverse events like rashes from amivantamab, emphasizing the benefits of a well-coordinated team and the value of experience in responding to reactions.

EP: 1.Managing Treatment-Related Rashes in Patients With EGFR-Mutated NSCLC

EP: 2.Managing Treatment-Related Diarrhea in Patients With EGFR-Mutated NSCLC

EP: 3.Implementing Dose Reductions and Dose Holds in Patients With EGFR-Mutated NSCLC Receiving TKIs

EP: 4.Multidisciplinary Management of Treatment-Related Adverse Events in Patients With EGFR-Mutated NSCLC

EP: 5.Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation

Now Viewing

EP: 6.Educating Patients and Clinical Staff on Infusion-Related Adverse Reactions Seen With Amivantamab in NSCLC With EGFR Exon 20 Mutations

EP: 7.Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC

EP: 8.Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

EP: 9.EGFR Mutations in Patients With NSCLC

EP: 10.Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

EP: 11.Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC

EP: 12.The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

EP: 13.Multidisciplinary Care, Approval Updates, and Future Research in NSCLC

EP: 14.Treatment Approaches for Patients With EGFR-Mutant NSCLC

EP: 15.Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

EP: 16.Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

EP: 17.Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

EP: 18.Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

EP: 19.The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

EP: 20.Unmet Needs and Future Perspectives in NSCLC Treatment

EP: 21.New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Related Content

Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients

ONCOLOGY Staff

June 19th 2025

Article

Experts discuss innovative treatments for extensive-stage small cell lung cancer, highlighting tarlatamab's potential and management of adverse effects.

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP

June 16th 2025

Podcast

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Sacituzumab Tirumotecan Enhances Efficacy in Pretreated EGFR-Mutant NSCLC

Roman Fabbricatore

June 9th 2025

Article

Sacituzumab tirumotecan showed a manageable safety profile compared to docetaxel in patients with EGFR-mutant advanced non–small cell lung cancer.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Leticia Nogueira, PhD, MPH

March 31st 2025

Podcast

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

$Twice-Daily Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC$

Twice-Daily Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Tim Cortese

June 6th 2025

Article

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

Sacituzumab Tirumotecan Improves Response vs Docetaxel in EFGR+ NSCLC

Ashley Chan

June 5th 2025

Article

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

Related Content

Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients

ONCOLOGY Staff

June 19th 2025

Article

Experts discuss innovative treatments for extensive-stage small cell lung cancer, highlighting tarlatamab's potential and management of adverse effects.

Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP

June 16th 2025

Podcast

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Sacituzumab Tirumotecan Enhances Efficacy in Pretreated EGFR-Mutant NSCLC

Roman Fabbricatore

June 9th 2025

Article

Sacituzumab tirumotecan showed a manageable safety profile compared to docetaxel in patients with EGFR-mutant advanced non–small cell lung cancer.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Leticia Nogueira, PhD, MPH

March 31st 2025

Podcast

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

$Twice-Daily Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC$

Twice-Daily Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Tim Cortese

June 6th 2025

Article

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

Sacituzumab Tirumotecan Improves Response vs Docetaxel in EFGR+ NSCLC

Ashley Chan

June 5th 2025

Article

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Educating Patients and Clinical Staff on Infusion-Related Adverse Reactions Seen With Amivantamab in NSCLC With EGFR Exon 20 Mutations

EP: 1.Managing Treatment-Related Rashes in Patients With EGFR-Mutated NSCLC

EP: 2.Managing Treatment-Related Diarrhea in Patients With EGFR-Mutated NSCLC

EP: 3.Implementing Dose Reductions and Dose Holds in Patients With EGFR-Mutated NSCLC Receiving TKIs

EP: 4.Multidisciplinary Management of Treatment-Related Adverse Events in Patients With EGFR-Mutated NSCLC

EP: 5.Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation

EP: 6.Educating Patients and Clinical Staff on Infusion-Related Adverse Reactions Seen With Amivantamab in NSCLC With EGFR Exon 20 Mutations

EP: 7.Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC

EP: 8.Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

EP: 9.EGFR Mutations in Patients With NSCLC

EP: 10.Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

EP: 11.Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC

EP: 12.The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

EP: 13.Multidisciplinary Care, Approval Updates, and Future Research in NSCLC

EP: 14.Treatment Approaches for Patients With EGFR-Mutant NSCLC

EP: 15.Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

EP: 16.Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

EP: 17.Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

EP: 18.Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

EP: 19.The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

EP: 20.Unmet Needs and Future Perspectives in NSCLC Treatment

EP: 21.New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies

Newsletter